Caris Life Sciences released interim Achieve 1 validation results for its Caris Detect multicancer early detection (MCED) assay. The test showed stage‑dependent sensitivity—~57% for stage I, ~70% for stage II, ~77% for stage III and ~99% for stage IV—while achieving about 95% specificity in an undiagnosed screening cohort. Caris said the data support its planned Q2 commercial launch, with blinded validation ongoing. MCED tests use circulating tumor DNA (ctDNA) and other signatures to detect cancers from blood; sensitivity typically increases with tumor burden, while specificity measures the false‑positive rate in healthy or non‑cancer populations.